ABSTRACT

To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress.

An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I):

$$\begin{array}{c|c}
\mathbf{R}^{1} & \mathbf{N} \\
\mathbf{N} & \mathbf{N} \\
\mathbf{N} & \mathbf{N} \\
\mathbf{R}^{3} & \mathbf{A} \\
\end{array}$$

$$\begin{array}{c|c}
\mathbf{R}^{1} & \mathbf{Y} \\
\end{array}$$

$$\begin{array}{c|c}
\mathbf{I} & \mathbf{I} \\
\end{array}$$

[wherein each of R^1 , R^2 and R^3 is independently a hydrogen atom or a C_{1-6} alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C_{1-8} alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.